ALM
MCID: ACR014
MIFTS: 45

Acral Lentiginous Melanoma (ALM) malady

Categories: Rare diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Acral Lentiginous Melanoma

About this section

Aliases & Descriptions for Acral Lentiginous Melanoma:

Name: Acral Lentiginous Melanoma 11 48 13
Acral Lentiginous Malignant Melanoma of Skin 48
Acral Lentiginous Melanoma, Malignant 11
Acral Lentiginous Malignant Melanoma 68
 
Malignant Acral Lentiginous Melanoma 11
Palmar/plantar Melanoma 48
Subungual Melanoma 48
Alm 48

Classifications:



External Ids:

Disease Ontology11 DOID:6367

Summaries for Acral Lentiginous Melanoma

About this section
NIH Rare Diseases:48 Acral lentiginous melanoma (alm) is a type of melanoma that occurs on the palms of the hands or the soles of the feet. the condition can develop in normal-appearing skin or within an existing mole. alm begins as a flat patch of discolored skin that may enlarge slowly over time. although the cancer cells often remain contained at the skins surface (epidermis) initially, alm can become invasive and spread as the condition advances. like other flat forms of melanoma, it can be recognized by the abcde rule. although alm affects men and women of all skin colors equally, is it most commonly diagnosed in people over age 40. the underlying cause of alm is poorly understood. it is not related to sun exposure like other forms of skin cancer. initial treatment generally consists of surgery to remove the skin lesion. additional therapy (such as radiation therapy or immunotherapy) may then be recommended depending on the severity of the condition. last updated: 4/3/2017

MalaCards based summary: Acral Lentiginous Melanoma, also known as acral lentiginous malignant melanoma of skin, is related to alstrom syndrome and melanoma, and has symptoms including macule An important gene associated with Acral Lentiginous Melanoma is NRAS (NRAS Proto-Oncogene, GTPase), and among its related pathways are Thyroid cancer and Long-term depression. Affiliated tissues include skin, lymph node and brain, and related mouse phenotypes are Decreased substrate adherent cell growth and limbs/digits/tail.

Disease Ontology:11 A skin melanoma that is characterized by slow growth of a small pigmented spot on the skin with a clearly defined edge, surrounded by normal-appearing skin and occurs on occurs on non hair-bairing surfaces including hands and feet, subungual sites, and fingers or toes.

Wikipedia:71 Acral lentiginous melanoma is a kind of lentiginous skin melanoma. Melanoma is a potentially serious... more...

Related Diseases for Acral Lentiginous Melanoma

About this section

Diseases related to Acral Lentiginous Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 82)
idRelated DiseaseScoreTop Affiliating Genes
1alstrom syndrome11.1
2melanoma11.0
3verrucous papilloma10.2KIT, NRAS
4cerebral arterial disease10.2KIT, NRAS
5brachydactyly tibial hypoplasia10.2CDKN2A, TERT
6pseudomonas stutzeri infections10.2BRAF, NRAS
7rdh12-related leber congenital amaurosis10.2BRAF, NRAS
8diffuse glomerulonephritis10.2KIT, NRAS
9splenic manifestation of prolymphocytic leukemia10.2BRAF, NRAS
10gallbladder pleomorphic giant cell adenocarcinoma10.1CDKN2A, NRAS
11adult epithelioid sarcoma10.1CDKN2A, NRAS
12ossifying fibromyxoid tumor10.1CDKN2A, NRAS
13vulva basal cell carcinoma10.1CDKN2A, KIT
14fragile x-associated tremor/ataxia syndrome10.1CDKN2A, KIT
15stomach diverticulosis10.1BRAF, KIT
16uterine corpus leiomyomatosis10.1CDKN2A, NRAS
17vaginal yolk sac tumor10.1KIT, NRAS
18spondylarthropathy10.1BRAF, CDKN2A
19extranodal nasal nk/t cell lymphoma10.1CDKN2A, KIT
20plasmodium ovale malaria10.1CDKN2A, KIT
21retroperitoneal leiomyosarcoma10.1KIT, NRAS
22pacinian tumor10.1CDKN2A, KIT
23monkeypox10.1KIT, PTEN
24familial hyperaldosteronism10.1KIT, NRAS
25small intestinal sarcoma10.1KIT, PTEN
26sarcoma10.1
27laryngitis10.1
28urethral verrucous carcinoma10.1CDKN2A, PTEN
29ganglioneuroblastoma10.0MET, TERT
30charcot-marie-tooth disease type 2n10.0CDKN2A, TERT
31multifocal osteogenic sarcoma10.0CDKN2A, KIT
32vulval paget's disease10.0CDKN2A, KIT, NRAS
33facial hemiatrophy10.0CDKN2A, KIT, NRAS
34nelson syndrome10.0CDKN2A, KIT, NRAS
35anal neuroendocrine tumor10.0CDKN2A, MET
36alpha chain disease10.0CDKN2A, KIT, NRAS
37leukemia, acute myeloid10.0KIT, NRAS, TERT
38house allergic alveolitis10.0CDKN2A, MET
39myxedema10.0CDKN2A, PTEN
40nodular cutaneous amyloidosis10.0CDKN2A, TERT
41lattice corneal dystrophy10.0BRAF, CDKN2A, NRAS
42parotid gland adenoid cystic carcinoma10.0KIT, NRAS, PTEN
43lice infestation9.9KIT, MET
44hepatic flexure cancer9.9CDKN2A, PTEN, TERT
45nevoid hypermelanosis, linear and whorled9.9CDKN2A, PTEN, TERT
46muscular dystrophy-dystroglycanopathy , type a, 109.9BRAF, NRAS, PTEN
47interstitial lung disease9.9CDKN2A, PTEN
48psoriatic arthritis9.9
49multiple myeloma9.9
50arthritis9.9

Graphical network of the top 20 diseases related to Acral Lentiginous Melanoma:



Diseases related to acral lentiginous melanoma

Symptoms & Phenotypes for Acral Lentiginous Melanoma

About this section

UMLS symptoms related to Acral Lentiginous Melanoma:


macule

GenomeRNAi Phenotypes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00193-A-39.0BRAF, KIT, MET

MGI Mouse Phenotypes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

41 (show all 23)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053718.5KIT, MET, NRAS, PTEN
2MP:00011868.5BRAF, CDKN2A, KIT, NRAS, PTEN
3MP:00053898.4BRAF, CDKN2A, KIT, PTEN, TERT
4MP:00053908.2BRAF, CDKN2A, KIT, PTEN, TERT
5MP:00107718.0BRAF, CDKN2A, KIT, NRAS, PTEN
6MP:00053697.7BRAF, CDKN2A, KIT, MET, PTEN
7MP:00053807.6BRAF, CDKN2A, KIT, MET, NRAS, PTEN
8MP:00028737.5BRAF, KIT, MET, NRAS, PTEN, TERT
9MP:00053917.5BRAF, CDKN2A, KIT, MET, NRAS, PTEN
10MP:00053867.5BRAF, CDKN2A, KIT, MET, NRAS, PTEN
11MP:00053977.5BRAF, CDKN2A, KIT, NRAS, PTEN, TERT
12MP:00053857.3BRAF, CDKN2A, KIT, MET, NRAS, PTEN
13MP:00053887.3BRAF, CDKN2A, KIT, MET, PTEN, TERT
14MP:00020067.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
15MP:00036317.1BRAF, CDKN2A, KIT, MET, PTEN, TERT
16MP:00053767.1BRAF, CDKN2A, KIT, MET, NRAS, PTEN
17MP:00107687.0BRAF, CDKN2A, KIT, MET, NRAS, PTEN
18MP:00053847.0BRAF, CDKN2A, KIT, MET, NRAS, PTEN
19MP:00053787.0BRAF, CDKN2A, KIT, MET, NRAS, PTEN
20MP:00053877.0BRAF, CDKN2A, KIT, MET, NRAS, PTEN
21MP:00053816.9BRAF, CDKN2A, KIT, MET, NRAS, PTEN
22MP:00053706.9BRAF, CDKN2A, KIT, MET, NRAS, PTEN
23MP:00053796.8BRAF, CDKN2A, KIT, MET, NRAS, PTEN

Drugs & Therapeutics for Acral Lentiginous Melanoma

About this section

Drugs for Acral Lentiginous Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Dasatinibapproved, investigationalPhase 2285302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
2
Sunitinibapproved, investigationalPhase 2510341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
3
PembrolizumabapprovedPhase 25071374853-91-4
Synonyms:
Keytruda
 
MK-3475
lambrolizumab
4
nivolumabapprovedPhase 2424946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
5
DabrafenibapprovedPhase 28444462760, 44516822
Synonyms:
BRAF inhibitor GSK2118436
Dabrafenib
 
GSK2118436
GSK2118436a
Tafinlar
dabrafenib
6
TrametinibapprovedPhase 2131871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
7
CediranibinvestigationalPhase 293288383-20-09933475
Synonyms:
288383-20-0
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
790713-41-6
AKOS005145767
AZD 2171
AZD-2171
AZD2171
AZD2171, Recentin, Cediranib
CHEMBL491473
CID9933475
 
Cediranib
Cediranib (USAN/INN)
Cediranib maleate
D08881
EC-000.2328
Kinome_3318
M6294
NSC-732208
Recentin
S1017_Selleck
UNII-NQU9IPY4K9
ZD-2171
cediranib
8
Maleic acidexperimentalPhase 2296110-16-7444266
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(2Z)-but-2-enedioate
(2Z)-but-2-enedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(z)-butenedioate
(z)-butenedioic acid
2-Butenedioate
2-Butenedioic acid
Cis-butenedioate
Cis-butenedioic acid
 
H2male
Kyselina maleinova
MAE
Maleate
Maleic acid
Maleic acid [NA2215]
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Toxilic acid
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
9Protein Kinase InhibitorsPhase 23689
10Angiogenesis InhibitorsPhase 24257
11Angiogenesis Modulating AgentsPhase 24185
12Imatinib MesylatePhase 2600123596
13AntibodiesPhase 26394
14Antibodies, MonoclonalPhase 24039
15ImmunoglobulinsPhase 26394
16tyrosineNutraceuticalPhase 2699
17
Ganciclovirapproved, investigationalPhase 115382410-32-03454
Synonyms:
106931-35-5
107910-75-8 (mono-hydrochloride salt)
2'-NDG
2'-Nor-2'-deoxyguanosine
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
82410-32-0
86357-12-2
9-((1,3-Dihydroxy-2-propoxy)methyl)guanine
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
96551-29-0
AC-12604
AC1L1FZ2
AC1Q52OB
AKOS004119898
BB_NC-1042
BIDD:GT0783
BIOLF-62
BPBio1_000877
BSPBio_000797
BW 759
BW 759U
BW-759U
BW-795
BW-B 759U
Biolf 62
CAS-82410-32-0
CCRIS 9212
CHEBI:465284
CHEMBL182
CID3454
CPD000058324
Citovirax
Cymevan
Cymeven
Cymevene
Cytovene
Cytovene (TN)
Cytovene-IV
D00333
DB01004
DRG-0018
EU-0100539
 
G 2536
G2536_SIGMA
GA2
GANCICLOVIR SODIUM
GCV & 1110U81
GCV & MSL
Ganciclovir
Ganciclovir & C34-dgA immunotoxin
Ganciclovir & D5-dgA immunotoxin
Ganciclovir (JAN/USP/INN)
Ganciclovir [USAN:INN:BAN:JAN]
Ganciclovirum
Ganciclovirum [Latin]
Gancyclovir
Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody
HHEMG
HMS1570H19
HMS2090K08
HSDB 6512
Hydroxyacyclovir
I07-0010
IN1478
LS-73939
Lopac-G-2536
Lopac0_000539
MB3795
MLS000028481
MLS001077349
MolPort-000-758-398
MolPort-002-507-301
NCGC00015471-01
NCGC00015471-02
NCGC00015471-03
NCGC00015471-06
NCGC00093928-01
NCGC00093928-02
NCGC00168567-01
PDSP1_000816
PDSP2_000803
Prestwick0_000839
Prestwick1_000839
Prestwick2_000839
Prestwick3_000839
Prestwick_1068
RS-21592
SAM002548936
SMP2_000038
SMR000058324
SPBio_002718
ST-605
STK801910
UNII-P9G3CKZ4P5
Virgan
Vitrasert
Vitrasert (TN)
ZINC00001505
Zirgan
ganciclovir
nchembio.87-comp3
18Nucleic Acid Synthesis InhibitorsPhase 14962
19Ganciclovir triphosphatePhase 1153
20Anti-Infective AgentsPhase 122062
21Antiviral AgentsPhase 19967

Interventional clinical trials:

(show all 15)
idNameStatusNCT IDPhase
1Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By SurgeryUnknown statusNCT00700882Phase 2
2SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous MelanomaCompletedNCT00577382Phase 2
3A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has SpreadCompletedNCT01395121Phase 2
4Imatinib in Patients With Mucosal or Acral/Lentiginous MelanomaCompletedNCT00424515Phase 2
5Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00470470Phase 2
6Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged MelanomaCompletedNCT00788775Phase 2
7AZD2171 in Treating Patients With Recurrent or Stage IV MelanomaCompletedNCT00243061Phase 2
8Pembrolizumab in Advanced/Metastatic Acral Lentiginous MelanomaRecruitingNCT02875132Phase 2
9A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With IpilimumabRecruitingNCT02978443Phase 2
10Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive MelanomaRecruitingNCT02083354Phase 2
11Dinaciclib in Treating Patients With Stage IV MelanomaActive, not recruitingNCT00937937Phase 2
12Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged MelanomaTerminatedNCT01092728Phase 2
13Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV MelanomaTerminatedNCT01120275Phase 2
14Gene Therapy and Ganciclovir in Treating Patients With Stage IV MelanomaCompletedNCT00005057Phase 1
15Study of Families With MelanomaRecruitingNCT00445783

Search NIH Clinical Center for Acral Lentiginous Melanoma

Genetic Tests for Acral Lentiginous Melanoma

About this section

Anatomical Context for Acral Lentiginous Melanoma

About this section

MalaCards organs/tissues related to Acral Lentiginous Melanoma:

36
Skin, Lymph node, Brain

Publications for Acral Lentiginous Melanoma

About this section

Articles related to Acral Lentiginous Melanoma:

(show top 50)    (show all 121)
idTitleAuthorsYear
1
Insulin-Like Growth Factor II mRNA-Binding Protein 3 Expression Correlates with Poor Prognosis in Acral Lentiginous Melanoma. (26796627)
2016
2
Survival of acral lentiginous melanoma in the National Cancer Institute of Colombia. (27518480)
2016
3
Histopathological diagnosis of acral lentiginous melanoma in early stages. (27601330)
2016
4
Acral Lentiginous Melanoma. (26601870)
2016
5
Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. (26709572)
2016
6
Acral lentiginous melanoma with multiple brain metastases in an Indian male. (27559525)
2016
7
Erratum to A. (27393792)
2016
8
Amelanotic acral lentiginous melanoma mimicking diabetic ulcer: a challenge to diagnose and treat. (26679765)
2016
9
Rare cause of non-healing foot wound - acral lentiginous melanoma. Case Report. (26994380)
2016
10
Hidden acral lentiginous melanoma with cutaneous metastases masquerading as Kaposi's sarcoma in an HIV-positive Indian man. (26838298)
2016
11
Focal invasiveness in complete histological analyses of a large acral lentiginous melanoma. (26088594)
2015
12
IMAGES IN CLINICAL MEDICINE. Acral Lentiginous Melanoma. (26535515)
2015
13
The distribution pattern of HMB-45-positive cells is helpful for the diagnosis of early acral lentiginous melanoma in situ. (25773399)
2015
14
Reconstruction of large wounds using a combination of negative pressure wound therapy and punch grafting after excision of acral lentiginous melanoma on the foot. (26173565)
2015
15
Screening for Acral Lentiginous Melanoma in Dark-Skinned Individuals. (26083954)
2015
16
MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma. (26588333)
2015
17
Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy? (25455840)
2015
18
Acral lentiginous melanoma of the foot misdiagnosed as a traumatic ulcer a cautionary case. (25815661)
2015
19
Reflectance confocal microscopy features of acral lentiginous melanoma: a comparative study with acral nevi. (26428577)
2015
20
Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells. (25252087)
2014
21
Two Spanish cases of Atypical Melanosis of the Foot, an early stage of Acral Lentiginous Melanoma in situ. (25323966)
2014
22
Comparison of dermatoscopic images of acral lentiginous melanoma and acral melanocytic nevus occurring on body weight-bearing areas. (25396085)
2014
23
Acral Lentiginous Melanoma - Misdiagnosis, referral delay and 5 years specific survival according to site. (25027337)
2014
24
Indolent Subtype Acral Lentiginous Melanoma With Long Radial Growth Phase: A Dermatopathological Pitfall. (25072690)
2014
25
TERT gene amplification is associated with poor outcome in acral lentiginous melanoma. (25219713)
2014
26
Laryngeal metastases of acral lentiginous melanoma: Narrow band imaging. (25488159)
2014
27
Recurrent acral lentiginous melanoma in situ suggesting the field cell theory. (25473243)
2014
28
Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study. (24882974)
2014
29
Acral lentiginous melanoma: indolent subtype with long radial growth phase. (24556899)
2014
30
TERT promoter mutation is uncommon in acral lentiginous melanoma. (24588324)
2014
31
Psoriatic arthritis with acral lentiginous melanoma: role for methotrexate? (24249911)
2013
32
Acral lentiginous melanoma of the toe treated using Mohs surgery with sparing of the digit and subsequent reconstruction using split-thickness skin graft. (22931051)
2013
33
Clinical presentation of acral lentiginous melanoma: a descriptive study. (22959666)
2013
34
Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma. (23362874)
2013
35
Comparison of negative pressure wound therapy and secondary intention healing after excision of acral lentiginous melanoma on the foot. (23362968)
2013
36
Conservative surgical treatment of a thin acral lentiginous melanoma of the thumb with no recurrences: a case report. (23742286)
2013
37
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. (23993026)
2013
38
Traumatic Hematoma in a Palmoplantar wart Mimicking Acral Lentiginous Melanoma. (23060711)
2012
39
Consumption of the epidermis in acral lentiginous melanoma. (22574622)
2012
40
Unique prognostic factors in acral lentiginous melanoma. (23022254)
2012
41
Popliteal sentinel lymph node biopsy is important in malignant melanoma of the distal lower extremities: a case report of acral lentiginous melanoma with simultaneous inguinal and popliteal lymph node micrometastases. (22157852)
2012
42
Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb. (20545949)
2011
43
Acral junctional nevus versus acral lentiginous melanoma in situ: a differential diagnosis that should be based on clinicopathologic correlation. (21732773)
2011
44
Acral Lentiginous Melanoma Developing during Long-standing Atypical Melanosis: Usefulness of Dermoscopy for Detection of Early Acral Melanoma. (21909219)
2011
45
The "spaghetti technique": an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma). (21167406)
2011
46
Acral lentiginous melanoma. (21549241)
2011
47
Letter: Acral-lentiginous melanoma: Report of 15 cases. (21272506)
2011
48
Comparison of secondary intention healing and full-thickness skin graft after excision of acral lentiginous melanoma on foot. (21615605)
2011
49
Acral lentiginous melanoma: a case control study and guidelines update. (21541184)
2011
50
Unilateral lichen planus pigmentosus mimicking acral lentiginous melanoma. (20677541)
2010

Variations for Acral Lentiginous Melanoma

About this section

Cosmic variations for Acral Lentiginous Melanoma:

8 (show top 50)    (show all 60)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM1290KITskin,acral,malignant melanoma,acral lentiginousc.1727T>Cp.L576P22
2COSM476BRAFskin,acral,malignant melanoma,acral lentiginousc.1799T>Ap.V600E22
3COSM562NRASskin,acral,malignant melanoma,acral lentiginousc.34G>Tp.G12C22
4COSM1257KITskin,acral,malignant melanoma,acral lentiginousc.1679T>Ap.V560D22
5COSM1166809PTENskin,acral,malignant melanoma,acral lentiginousc.333G>Ap.W111*22
6COSM1255KITskin,acral,malignant melanoma,acral lentiginousc.1676T>Cp.V559A22
7COSM584NRASskin,acral,malignant melanoma,acral lentiginousc.182A>Gp.Q61R22
8COSM460BRAFskin,acral,malignant melanoma,acral lentiginousc.1406G>Cp.G469A22
9COSM235682KITskin,acral,malignant melanoma,acral lentiginousc.1965T>Gp.N655K22
10COSM580NRASskin,acral,malignant melanoma,acral lentiginousc.181C>Ap.Q61K22
11COSM583NRASskin,acral,malignant melanoma,acral lentiginousc.182A>Tp.Q61L22
12COSM1304KITskin,acral,malignant melanoma,acral lentiginousc.1924A>Gp.K642E22
13COSM18682KITskin,acral,malignant melanoma,acral lentiginousc.2468A>Gp.Y823C22
14COSM1430154KITskin,acral,malignant melanoma,acral lentiginousc.1715A>Gp.D572G22
15COSM29015KITskin,acral,malignant melanoma,acral lentiginousc.1673A>Gp.K558R22
16COSM565NRASskin,subungual,malignant melanoma,acral lentiginousc.35G>Cp.G12A16
17COSM33972KITskin,hand,malignant melanoma,acral lentiginousc.1915T>Cp.S639P16
18COSM110724BAP1skin,sole,malignant melanoma,acral lentiginousc.2090C>Gp.S697C16
19COSM1651643KITskin,sole,malignant melanoma,acral lentiginousc.1420G>Ap.V474I16
20COSM1138BRAFskin,sole,malignant melanoma,acral lentiginousc.1823A>Gp.H608R16
21COSM253327NRASskin,acral,malignant melanoma,NSc.176C>Ap.A59D14
22COSM566NRASskin,NS,malignant melanoma,acral lentiginousc.35G>Tp.G12V14
23COSM564NRASskin,NS,malignant melanoma,acral lentiginousc.35G>Ap.G12D14
24COSM467BRAFskin,acral,malignant melanoma,NSc.1781A>Gp.D594G14
25COSM1651644KITskin,NS,malignant melanoma,acral lentiginousc.2449A>Cp.I817L14
26COSM1273KITskin,acral,malignant melanoma,NSc.1696A>Gp.N566D14
27COSM33966KITskin,acral,malignant melanoma,NSc.1726C>Tp.L576F14
28COSM253329BRAFskin,acral,malignant melanoma,NSc.1811G>Ap.W604*14
29COSM107839GRIN2Askin,NS,malignant melanoma,acral lentiginousc.2786C>Tp.S929F14
30COSM521KRASskin,NS,malignant melanoma,acral lentiginousc.35G>Ap.G12D14
31COSM577NRASskin,NS,malignant melanoma,acral lentiginousc.52G>Ap.A18T14
32COSM12736CDKN2Askin,NS,malignant melanoma,acral lentiginousc.104G>Tp.G35V14
33COSM253324BRAFskin,acral,malignant melanoma,NSc.1349G>Ap.W450*14
34COSM133756KITskin,acral,malignant melanoma,NSc.2542T>Cp.F848L14
35COSM253328BRAFskin,acral,malignant melanoma,NSc.1396G>Ap.G466R14
36COSM133763KITskin,acral,malignant melanoma,NSc.1657T>Ap.Y553N14
37COSM573NRASskin,NS,malignant melanoma,acral lentiginousc.38G>Ap.G13D14
38COSM144512KITskin,NS,malignant melanoma,acral lentiginousc.1904A>Gp.E635G14
39COSM107986GRIN2Askin,NS,malignant melanoma,acral lentiginousc.1774A>Gp.K592E14
40COSM133765KITskin,acral,malignant melanoma,NSc.1898A>Gp.E633G14
41COSM3724522NRASskin,NS,malignant melanoma,acral lentiginousc.184G>Cp.E62Q14
42COSM133767KITskin,acral,malignant melanoma,NSc.2558G>Ap.W853*14
43COSM144520KITskin,acral,malignant melanoma,NSc.1694G>Ap.G565E14
44COSM29529RB1skin,NS,malignant melanoma,acral lentiginousc.1411C>Tp.Q471*14
45COSM250098KITskin,acral,malignant melanoma,NSc.1656G>Ap.M552I14
46COSM133757KITskin,acral,malignant melanoma,NSc.2486C>Tp.A829V14
47COSM1578125KITskin,NS,malignant melanoma,acral lentiginousc.2591C>Tp.S864F14
48COSM133769KITskin,acral,malignant melanoma,NSc.2576T>Cp.L859P14
49COSM133762KITskin,acral,malignant melanoma,NSc.2450T>Cp.I817T14
50COSM563NRASskin,NS,malignant melanoma,acral lentiginousc.34G>Ap.G12S14

Expression for genes affiliated with Acral Lentiginous Melanoma

About this section
Search GEO for disease gene expression data for Acral Lentiginous Melanoma.

Pathways for genes affiliated with Acral Lentiginous Melanoma

About this section

Pathways related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 32)
idSuper pathwaysScoreTop Affiliating Genes
19.6BRAF, NRAS
29.6BRAF, NRAS
39.6BRAF, NRAS
49.5NRAS, PTEN
59.3MET, NRAS
69.2CDKN2A, NRAS, TERT
7
Show member pathways
9.1BRAF, KIT, NRAS
8
Show member pathways
9.1BRAF, CDKN2A, NRAS
9
Show member pathways
9.1BRAF, CDKN2A, NRAS
109.0CDKN2A, NRAS, PTEN
11
Show member pathways
9.0BRAF, NRAS, PTEN
12
Show member pathways
9.0BRAF, NRAS, PTEN
138.8BRAF, CDKN2A, PTEN
148.8BRAF, MET, NRAS
15
Show member pathways
8.5BRAF, MET, PTEN
16
Show member pathways
8.5BRAF, KIT, NRAS, PTEN
178.4BRAF, CDKN2A, NRAS, PTEN
18
Show member pathways
8.3BRAF, KIT, MET, NRAS
19
Show member pathways
8.3BRAF, KIT, MET, NRAS
208.2KIT, MET, NRAS, PTEN
21
Show member pathways
8.2KIT, MET, NRAS, PTEN
228.2KIT, MET, NRAS, PTEN
238.1CDKN2A, MET, NRAS, PTEN
24
Show member pathways
8.1BRAF, MET, NRAS, PTEN
25
Show member pathways
8.1BRAF, MET, NRAS, PTEN
26
Show member pathways
8.1BRAF, MET, NRAS, PTEN
27
Show member pathways
8.1BRAF, MET, NRAS, PTEN
28
Show member pathways
7.7BRAF, KIT, MET, NRAS, PTEN
29
Show member pathways
7.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
307.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
31
Show member pathways
7.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
32
Show member pathways
6.7BRAF, CDKN2A, KIT, MET, NRAS, PTEN

GO Terms for genes affiliated with Acral Lentiginous Melanoma

About this section

Cellular components related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytoplasmic side of plasma membraneGO:00098989.4KIT, PTEN

Biological processes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of endothelial cell apoptotic processGO:200035210.3BRAF, TERT
2myeloid progenitor cell differentiationGO:000231810.2BRAF, KIT
3cellular response to nerve growth factor stimulusGO:199009010.1BRAF, PTEN
4long-term synaptic potentiationGO:006029110.1BRAF, PTEN
5replicative senescenceGO:009039910.0CDKN2A, TERT
6somatic stem cell divisionGO:00481039.9CDKN2A, KIT
7regulation of axon regenerationGO:00486799.9BRAF, PTEN
8visual learningGO:00085429.5BRAF, KIT
9positive regulation of gene expressionGO:00106289.4BRAF, KIT, PTEN
10regulation of protein stabilityGO:00316479.4CDKN2A, PTEN, TERT
11phosphatidylinositol-mediated signalingGO:00480159.3KIT, MET, PTEN
12MAPK cascadeGO:00001659.0BRAF, KIT, MET, NRAS
13phosphorylationGO:00163108.8BRAF, CDKN2A, KIT, MET

Molecular functions related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1transmembrane receptor protein tyrosine kinase activityGO:00047149.2KIT, MET
2kinase activityGO:00163018.8BRAF, CDKN2A, KIT, MET
3nucleotide bindingGO:00001668.8BRAF, KIT, MET, NRAS

Sources for Acral Lentiginous Melanoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet